Rafferty Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.61M | Sell |
90,756
-11,375
| -11% | -$327K | 0.01% | 542 |
|
|
2025
Q1 | $3.43M | Buy |
102,131
+20,874
| +26% | +$700K | 0.01% | 447 |
|
|
2024
Q4 | $4.15M | Sell |
81,257
-16,193
| -17% | -$828K | 0.01% | 451 |
|
|
2024
Q3 | $4.98M | Sell |
97,450
-14,719
| -13% | -$752K | 0.02% | 427 |
|
|
2024
Q2 | $5.02M | Sell |
112,169
-104,680
| -48% | -$4.69M | 0.02% | 414 |
|
|
2024
Q1 | $10.2M | Sell |
216,849
-27,440
| -11% | -$1.28M | 0.04% | 261 |
|
|
2023
Q4 | $8.69M | Buy |
244,289
+46,548
| +24% | +$1.66M | 0.04% | 317 |
|
|
2023
Q3 | $5.88M | Buy |
197,741
+59,555
| +43% | +$1.77M | 0.03% | 356 |
|
|
2023
Q2 | $2.49M | Buy |
138,186
+9,478
| +7% | +$171K | 0.01% | 586 |
|
|
2023
Q1 | $2.07M | Buy |
128,708
+22,210
| +21% | +$357K | 0.01% | 604 |
|
|
2022
Q4 | $1.95M | Buy |
106,498
+31,045
| +41% | +$568K | 0.02% | 586 |
|
|
2022
Q3 | $1.48M | Buy |
75,453
+30,684
| +69% | +$603K | 0.02% | 576 |
|
|
2022
Q2 | $835K | Sell |
44,769
-33,366
| -43% | -$622K | 0.01% | 704 |
|
|
2022
Q1 | $1.72M | Buy |
78,135
+26,023
| +50% | +$571K | 0.01% | 654 |
|
|
2021
Q4 | $1.48M | Buy |
52,112
+24,599
| +89% | +$699K | 0.01% | 761 |
|
|
2021
Q3 | $579K | Buy |
+27,513
| New | +$579K | ﹤0.01% | 1009 |
|